Ticker Details
Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.
IPO Date:	June 1, 1998
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$183.7M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.15 | 2.84%
Avg Daily Range (30 D):	$0.05 | 2.02%
Avg Daily Range (90 D):	$0.06 | 2.54%

Institutional Daily Volume
Avg Daily Volume:	.45M
Avg Daily Volume (30 D):	.96M
Avg Daily Volume (90 D):	1.01M

Trade Size
Avg Trade Size (Sh.):	324
Avg Trade Size (Sh.) (30 D):	167
Avg Trade Size (Sh.) (90 D):	187

Institutional Trades
Total Institutional Trades:	284
Avg Institutional Trade:	$1.6M
Avg Institutional Trade (30 D):	$.63M
Avg Institutional Trade (90 D):	$.6M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$4.86M
Avg Closing Trade (30 D):	$.63M
Avg Closing Trade (90 D):	$.63M
Avg Closing Volume:	617K

News

Mar 9, 2026 @ 10:00 AM Chiesi Global Rare Diseases and Protalix BioTherap... Source: Chiesi Global Rare Diseases / Protalix Biotherapeutics

Mar 26, 2025 @ 7:00 PM [Latest] Global Fabry Disease Treatment Market Siz... Source: Custom Market Insights

Jun 12, 2024 @ 3:45 PM Pluxee to acquire Cobee, an innovative Spanish dig... Source: Pluxee N.V

Jun 12, 2024 @ 3:45 PM Pluxee signe un accord pour l’acquisition d... Source: Pluxee N.V

Jun 12, 2024 @ 3:45 PM Pluxee firma un acuerdo para adquirir Cobee, empre... Source: Pluxee N.V

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.08	$-.07	$-.08
Diluted EPS	$-.08	$-.07	$-.08
Revenue	$52.74M	$9.12M	$52.74M
Gross Profit	$25.75M	$4.5M	$25.75M
Net Income / Loss	$-6.6M	$-5.5M	$-6.6M
Operating Income / Loss	$-5.5M	$-4.66M	$-5.5M
Cost of Revenue	$26.99M	$4.62M	$26.99M
Net Cash Flow	$-5.03M	$1.06M	$-5.03M
PE Ratio

Splits
Dec 20, 2019	1:10
Jan 03, 2007	1:10